What is Zacks Research's Estimate for Amarin Q2 Earnings?

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for Amarin in a research note issued to investors on Tuesday, June 3rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($0.60) for the quarter, up from their prior estimate of ($0.87). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($1.05) EPS, FY2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.19) EPS and FY2027 earnings at ($1.62) EPS.

A number of other research firms have also commented on AMRN. Wall Street Zen raised shares of Amarin from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on shares of Amarin from $20.00 to $7.00 and set a "sell" rating for the company in a research note on Thursday, April 17th.

Amarin Stock Up 7.3%

NASDAQ:AMRN traded up $0.87 during trading hours on Friday, reaching $12.72. 142,133 shares of the company's stock were exchanged, compared to its average volume of 74,707. The company has a market capitalization of $263.39 million, a P/E ratio of -141.33 and a beta of 0.71. Amarin has a 12 month low of $7.08 and a 12 month high of $16.60. The business's 50-day simple moving average is $10.31 and its two-hundred day simple moving average is $10.29.

Amarin (NASDAQ:AMRN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%.

Hedge Funds Weigh In On Amarin

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its stake in Amarin by 112.3% in the 1st quarter. Acadian Asset Management LLC now owns 3,791,515 shares of the biopharmaceutical company's stock worth $1,685,000 after purchasing an additional 2,005,713 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of Amarin by 449,522.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company's stock valued at $815,000 after buying an additional 1,811,574 shares during the period. Stonepine Capital Management LLC boosted its stake in shares of Amarin by 470.3% during the 1st quarter. Stonepine Capital Management LLC now owns 651,614 shares of the biopharmaceutical company's stock valued at $293,000 after buying an additional 537,357 shares during the period. LCM Capital Management Inc boosted its stake in shares of Amarin by 2.4% during the 1st quarter. LCM Capital Management Inc now owns 858,259 shares of the biopharmaceutical company's stock valued at $385,000 after buying an additional 20,000 shares during the period. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of Amarin during the 1st quarter valued at $25,000. Institutional investors and hedge funds own 22.25% of the company's stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.